JP2021517119A - 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 - Google Patents

腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 Download PDF

Info

Publication number
JP2021517119A
JP2021517119A JP2020546331A JP2020546331A JP2021517119A JP 2021517119 A JP2021517119 A JP 2021517119A JP 2020546331 A JP2020546331 A JP 2020546331A JP 2020546331 A JP2020546331 A JP 2020546331A JP 2021517119 A JP2021517119 A JP 2021517119A
Authority
JP
Japan
Prior art keywords
adenovirus
inhibitor
cdk4
combination
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020546331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517119A5 (cg-RX-API-DMAC7.html
Inventor
ホルム,ペル・ゾンネ
ナヴロート,ロマン
Original Assignee
クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン
クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン, クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン filed Critical クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン
Publication of JP2021517119A publication Critical patent/JP2021517119A/ja
Publication of JP2021517119A5 publication Critical patent/JP2021517119A5/ja
Priority to JP2024186627A priority Critical patent/JP2025013934A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020546331A 2018-03-05 2019-03-05 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 Pending JP2021517119A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024186627A JP2025013934A (ja) 2018-03-05 2024-10-23 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18000210 2018-03-05
EP18000210.7 2018-03-05
PCT/EP2019/000067 WO2019170283A1 (en) 2018-03-05 2019-03-05 Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024186627A Division JP2025013934A (ja) 2018-03-05 2024-10-23 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置

Publications (2)

Publication Number Publication Date
JP2021517119A true JP2021517119A (ja) 2021-07-15
JP2021517119A5 JP2021517119A5 (cg-RX-API-DMAC7.html) 2022-03-14

Family

ID=61569019

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546331A Pending JP2021517119A (ja) 2018-03-05 2019-03-05 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置
JP2024186627A Pending JP2025013934A (ja) 2018-03-05 2024-10-23 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024186627A Pending JP2025013934A (ja) 2018-03-05 2024-10-23 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置

Country Status (13)

Country Link
US (1) US20210038661A1 (cg-RX-API-DMAC7.html)
EP (1) EP3762004B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021517119A (cg-RX-API-DMAC7.html)
KR (2) KR20210031852A (cg-RX-API-DMAC7.html)
CN (1) CN112533620B (cg-RX-API-DMAC7.html)
AU (1) AU2019232768B2 (cg-RX-API-DMAC7.html)
CA (1) CA3092907A1 (cg-RX-API-DMAC7.html)
DK (1) DK3762004T3 (cg-RX-API-DMAC7.html)
ES (1) ES2965632T3 (cg-RX-API-DMAC7.html)
FI (1) FI3762004T3 (cg-RX-API-DMAC7.html)
HU (1) HUE064471T2 (cg-RX-API-DMAC7.html)
SG (1) SG11202007873VA (cg-RX-API-DMAC7.html)
WO (1) WO2019170283A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547885A (ja) * 2019-09-05 2022-11-16 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置
WO2024043322A1 (ja) * 2022-08-25 2024-02-29 富士フイルム株式会社 目的ウイルスの製造方法、および培養組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102341347B1 (ko) * 2019-11-28 2021-12-20 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512284A (ja) * 2002-05-27 2006-04-13 ホルム,ペル・ゾンネ アデノウイルスおよびそれをコードしている核酸の新たな使用
JP2006518589A (ja) * 2002-10-15 2006-08-17 ホルム,ペル・ゾンネ 新規アデノウイルス、それをコードする核酸及びその使用
JP2007511212A (ja) * 2003-11-14 2007-05-10 ホルム,ペル・ゾンネ 新規アデノウイルス、それをコードする核酸及びその使用
JP2016516407A (ja) * 2013-03-14 2016-06-09 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
WO2016178167A1 (en) * 2015-05-04 2016-11-10 Vcn Biosciences Sl Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment
JP2017501187A (ja) * 2013-12-31 2017-01-12 シュエンジュウ・ファーマ・カンパニー・リミテッド キナーゼ阻害剤及びその使用
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2012022496A2 (en) * 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
US9271988B2 (en) * 2011-07-01 2016-03-01 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer
AU2014272695B2 (en) * 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512284A (ja) * 2002-05-27 2006-04-13 ホルム,ペル・ゾンネ アデノウイルスおよびそれをコードしている核酸の新たな使用
JP2006518589A (ja) * 2002-10-15 2006-08-17 ホルム,ペル・ゾンネ 新規アデノウイルス、それをコードする核酸及びその使用
JP2007511212A (ja) * 2003-11-14 2007-05-10 ホルム,ペル・ゾンネ 新規アデノウイルス、それをコードする核酸及びその使用
JP2016516407A (ja) * 2013-03-14 2016-06-09 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
JP2017501187A (ja) * 2013-12-31 2017-01-12 シュエンジュウ・ファーマ・カンパニー・リミテッド キナーゼ阻害剤及びその使用
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法
WO2016178167A1 (en) * 2015-05-04 2016-11-10 Vcn Biosciences Sl Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANAL. BIOCHEM., vol. 421, JPN6024024291, 2012, pages 368 - 377, ISSN: 0005354480 *
CANCER TREAT. REV., vol. 45, JPN6024024290, 2016, pages 129 - 138, ISSN: 0005354481 *
DIGESTIVE DISEASES AND SCIENCES,2008年,VOL. 54,NO. 7,P.1425-1431, JPN6022054131, ISSN: 0005144309 *
EUROPEAN UROLOGY SUPPLEMENTS, vol. 14, no. 2, JPN6022054129, 2015, pages 32, ISSN: 0005144308 *
MOLECULAR ONCOLOGY, vol. 9, no. 4, JPN6022054132, 2014, pages 791 - 805, ISSN: 0005144310 *
NATURE COMMUNICATIONS,2022年8月10日,VOL. 13,NO. 1, #4689, JPN6022054134, ISSN: 0005144307 *
VIRUSES,2010年,VOL. 2,NO. 1,P.78-106, JPN6022054133, ISSN: 0005144306 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547885A (ja) * 2019-09-05 2022-11-16 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置
JP7834342B2 (ja) 2019-09-05 2026-03-24 クリニクム デア テクニシェン ウニフェルジテート ミュンヘン(ティーユーエム クリニクム) 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置
WO2024043322A1 (ja) * 2022-08-25 2024-02-29 富士フイルム株式会社 目的ウイルスの製造方法、および培養組成物

Also Published As

Publication number Publication date
WO2019170283A8 (en) 2019-11-07
CA3092907A1 (en) 2019-09-12
CN112533620A (zh) 2021-03-19
AU2019232768B2 (en) 2025-12-18
HUE064471T2 (hu) 2024-03-28
EP3762004B1 (en) 2023-09-13
EP3762004A1 (en) 2021-01-13
DK3762004T3 (da) 2023-11-27
AU2019232768A1 (en) 2020-09-03
CN112533620B (zh) 2025-03-28
US20210038661A1 (en) 2021-02-11
SG11202007873VA (en) 2020-09-29
ES2965632T3 (es) 2024-04-16
KR20260089640A (ko) 2026-06-15
RU2020132466A (ru) 2022-04-05
JP2025013934A (ja) 2025-01-28
KR20210031852A (ko) 2021-03-23
RU2020132466A3 (cg-RX-API-DMAC7.html) 2022-04-05
WO2019170283A1 (en) 2019-09-12
FI3762004T3 (fi) 2023-12-11

Similar Documents

Publication Publication Date Title
JP5618896B2 (ja) 新規アデノウイルス、それをコードする核酸及びその使用
JP6375273B2 (ja) 腫瘍選択的e1aおよびe1b変異体
JP5873893B2 (ja) アデノウイルスおよびそれをコードしている核酸の新たな使用
JP2025013934A (ja) 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置
JP6388593B2 (ja) E1bタンパク質の156rスプライシングアイソフォームの割合を増加させた腫瘍溶解性アデノウイルス
US20090270484A1 (en) WWOX Vectors and Uses in Treatment of Cancer
KR101527213B1 (ko) 동물 세포에서 다중 내성을 역전시키기 위한 방법
Holzmüller et al. YB‐1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma
JP7834342B2 (ja) 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置
KR20050061530A (ko) 신규한 아데노바이러스, 이를 암호화하는 핵산 및 이들의용도
KR20040077002A (ko) 개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터
RU2835886C1 (ru) Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента
RU2811278C2 (ru) Лечение опухолей комбинацией онколитического аденовируса и ингибитора cdk4/6
Wang et al. HSF1 overexpression enhances oncolytic effect of replicative adenovirus
WO2018067165A1 (en) Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
Kühnel et al. Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues
Li et al. microRNA response element‑regulated TIKI2 expression suppresses the tumorigencity of malignant gliomas
Klein Investigation of replication kinetics and cell killing capacity of the oncolytic adenovirus XVir-N-31 in conjunction with targeted therapy
Majhen et al. Vincristine-resistant human laryngeal carcinoma cells demonstrate increased Rous sarcoma virus promoter activity
Aguirre The oncolytic adenoviral AdΔΔ mutant sensitizes prostate cancer cells to mitoxantrone by promoting apoptosis and attenuating autophagy
Wang et al. Research HSF1 overexpression enhances oncolytic effect of replicative adenovirus
Abbas UNDERSTANDING THE RELATIONSHIP BETWEEN ONCOLYTIC AD5 DELETED E1b55KDA LYTIC INFECTION AND P53 IN MAMMALIAN CELLS
Strauss ANALYSIS OF RESISTANCE OF PRIMARY OVARIAN CANCER CELLS TO VIRAL ONCOLYSIS DISSER TAT ION zur Erlangung des akademischen Grades doctor rerum naturalium
Rivera Gonzalez Regulation of the prostate-specific hTGP (TGM4) gene and its potential use for prostate cancer gene therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240625